Obsidian Therapeutics Management

Management criteria checks 3/4

Obsidian Therapeutics' CEO is Madan Jagasia, appointed in Jan 2023, has a tenure of 3.67 years. total yearly compensation is $1.32M, comprised of 42.5% salary and 57.5% bonuses, including company stock and options. directly owns 1.46% of the company’s shares, worth $16.04M. The average tenure of the management team and the board of directors is 3 years and 4.9 years respectively.

Key information

Madan Jagasia

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage	42.54%
CEO tenure	3.7yrs
CEO ownership	1.5%
Management average tenure	3yrs
Board average tenure	4.9yrs

Recent management updates

Recent updates

Analysis Article • Aug 08

Here's Why We're Watching Obsidian Therapeutics' (NASDAQ:OBX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO Compensation Analysis

How has Madan Jagasia's remuneration changed compared to Obsidian Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2026	n/a	n/a	-US$94m
Mar 31 2026	n/a	n/a	-US$95m
Dec 31 2025	US$1m	US$560k	-US$101m

Compensation vs Market: Madan's total compensation ($USD1.32M) is below average for companies of similar size in the US market ($USD3.51M).

Compensation vs Earnings: Insufficient data to compare Madan's compensation with company performance.

CEO

Madan Jagasia (56 yo)

3.7yrs

Tenure

US$1,315,770

Compensation

Dr. Madan Jagasia, M.D., M.S., is Member of Medical Advisory Board of Bone Marrow & Cancer Foundation. Dr. Madan Jagasia is Chief Executive Officer and Director of Obsidian Therapeutics, Inc. since January...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Maria Fardis	Executive Chairman of the Board	4.9yrs	US$110.91k	0.16% $ 1.7m
Madan Jagasia	President	3.7yrs	US$1.32m	1.46% $ 16.0m
Dana Alexander	Chief Technical Officer	2.4yrs	US$690.00k	0.24% $ 2.6m
Parameswaran Hari	Chief Medical Officer	3.7yrs	US$723.95k	0.37% $ 4.1m
Julie Feder	Chief Financial Officer	less than a year	no data	no data
Caroline Code	Vice President of Corporate Development & Investor Relations	no data	no data	no data
Jennifer Peterson	Chief People Officer	no data	no data	no data
Peter Barrett	Secretary & Director	no data	no data	no data

3.0yrs

Average Tenure

58yo

Average Age

Experienced Management: OBX's management team is considered experienced (3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Maria Fardis	Executive Chairman of the Board	4.9yrs	US$110.91k	0.16% $ 1.7m
Madan Jagasia	President	3.7yrs	US$1.32m	1.46% $ 16.0m
Peter Barrett	Secretary & Director	11yrs	no data	no data
Lewis L. Lanier	Member of Scientific Advisory Board	no data	no data	no data
Matthew Norkunas	Independent Director	3.4yrs	US$45.72k	0.032% $ 351.3k
Michael Briskin	Chairman of Scientific Advisory Board	no data	no data	no data
Heidi Hagen	Independent Director	4.8yrs	US$52.09k	0.058% $ 637.3k
Robert Ross	Independent Director	6yrs	US$42.33k	0.070% $ 769.2k
Christopher Klebanoff	Member of Scientific Advisory Board	no data	no data	no data
Tom Wandless	Member of Scientific Advisory Board	no data	no data	no data

4.9yrs

Average Tenure

56.5yo

Average Age

Experienced Board: OBX's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/20 06:04
End of Day Share Price	2026/09/18 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Obsidian Therapeutics, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kelsey Goodwin	Piper Sandler Companies
Tyler Van Buren	TD Cowen
Samantha Corwin	William Blair & Company L.L.C.